These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 27160425)

  • 21. Transdermal scopolamine for prevention of motion sickness : clinical pharmacokinetics and therapeutic applications.
    Nachum Z; Shupak A; Gordon CR
    Clin Pharmacokinet; 2006; 45(6):543-66. PubMed ID: 16719539
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anticholinergic Versus Antihistaminic Treatment for Simulator Sickness Prevention.
    Ben-Ari O; Sarfati S; Gordon B; Assa A; Nakdimon I
    J Clin Pharmacol; 2023 Oct; 63(10):1119-1125. PubMed ID: 37491788
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Distinctive effects of modafinil and d-amphetamine on the homeostatic and circadian modulation of the human waking EEG.
    Chapotot F; Pigeau R; Canini F; Bourdon L; Buguet A
    Psychopharmacology (Berl); 2003 Mar; 166(2):127-38. PubMed ID: 12552359
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Side effects of antimotion sickness drugs.
    Wood CD; Manno JE; Manno BR; Redetzki HM; Wood M; Vekovius WA
    Aviat Space Environ Med; 1984 Feb; 55(2):113-6. PubMed ID: 6696702
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differential effects of a new central adrenergic agonist--modafinil--and D-amphetamine on sleep and early morning behaviour in young healthy volunteers.
    Saletu B; Frey R; Krupka M; Anderer P; Grünberger J; Barbanoj MJ
    Int J Clin Pharmacol Res; 1989; 9(3):183-95. PubMed ID: 2568348
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The stimulant effect of modafinil on wakefulness is not associated with an increase in anxiety in mice. A comparison with dexamphetamine.
    Simon P; Panissaud C; Costentin J
    Psychopharmacology (Berl); 1994 May; 114(4):597-600. PubMed ID: 7855221
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of psychostimulant drugs for amphetamine abuse or dependence.
    Pérez-Mañá C; Castells X; Torrens M; Capellà D; Farre M
    Cochrane Database Syst Rev; 2013 Sep; (9):CD009695. PubMed ID: 23996457
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of antimotion sickness drug side effects on performance.
    Wood CD; Manno JE; Manno BR; Redetzki HM; Wood MJ; Mims ME
    Aviat Space Environ Med; 1985 Apr; 56(4):310-6. PubMed ID: 3888169
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Motion sickness.
    Lovan WD
    Am Fam Physician; 1984 Jun; 29(6):117-22. PubMed ID: 6731246
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Space motion sickness medications: interference with biomedical parameters.
    Vernikos-Danellis J; Winget CM; Leach CS; Rosenblatt LS; Lyman J; Beljan JR
    Acta Astronaut; 1977; 4(11-12):1159-69. PubMed ID: 11829024
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modafinil alone and in combination with low dose amphetamine does not establish conditioned place preference in male Sprague-Dawley rats.
    Quisenberry AJ; Prisinzano TE; Baker LE
    Exp Clin Psychopharmacol; 2013 Jun; 21(3):252-8. PubMed ID: 23647093
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Motion sickness in cats: a symptom rating scale used in laboratory and flight tests.
    Suri KB; Crampton GH; Daunton NG
    Aviat Space Environ Med; 1979 Jun; 50(6):614-8. PubMed ID: 475712
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectiveness and duration of intramuscular antimotion sickness medications.
    Wood CD; Stewart JJ; Wood MJ; Mims M
    J Clin Pharmacol; 1992 Nov; 32(11):1008-12. PubMed ID: 1474161
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevalence, Predictors, and Prevention of Motion Sickness in Zero-G Parabolic Flights.
    Golding JF; Paillard AC; Normand H; Besnard S; Denise P
    Aerosp Med Hum Perform; 2017 Jan; 88(1):3-9. PubMed ID: 28061915
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transdermal scopolamine in the prevention of motion sickness at sea.
    Price NM; Schmitt LG; McGuire J; Shaw JE; Trobough G
    Clin Pharmacol Ther; 1981 Mar; 29(3):414-9. PubMed ID: 7009021
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Pharmacologic agents for preventing and treating motion sickness].
    Shashkov VS; Sabaev VV
    Kosm Biol Aviakosm Med; 1981; 15(1):9-18. PubMed ID: 6111621
    [No Abstract]   [Full Text] [Related]  

  • 37. The prevention of seasickness with hyoscine, benadryl, and phenergan.
    GLASER EM; HERVEY GR
    Lancet; 1951 Oct; 2(6687):749-53. PubMed ID: 14874498
    [No Abstract]   [Full Text] [Related]  

  • 38. Effects of dextroamphetamine, caffeine and modafinil on psychomotor vigilance test performance after 44 h of continuous wakefulness.
    Killgore WD; Rupp TL; Grugle NL; Reichardt RM; Lipizzi EL; Balkin TJ
    J Sleep Res; 2008 Sep; 17(3):309-21. PubMed ID: 18522689
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dopaminergic mediation of the discriminative stimulus functions of modafinil in rats.
    Quisenberry AJ; Baker LE
    Psychopharmacology (Berl); 2015 Dec; 232(24):4411-9. PubMed ID: 26374456
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Motion sickness: a modulatory role for the central cholinergic nervous system.
    Kohl RL; Homick JL
    Neurosci Biobehav Rev; 1983; 7(1):73-85. PubMed ID: 6300737
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.